Dr. Michela Perego, PhD - The Wistar Institute - Associate Staff Scientist

Dr. Michela Perego

PhD

The Wistar Institute

Associate Staff Scientist

philadelphia, PA | United States

Main Specialties: Allergy & Immunology

Additional Specialties: melanoma research-immunology


Top Author

Dr. Michela Perego, PhD - The Wistar Institute - Associate Staff Scientist

Dr. Michela Perego

PhD

Introduction

Primary Affiliation: The Wistar Institute - philadelphia, PA , United States

Specialties:

Additional Specialties:

Research Interests:

Education

Mar 2011
Open University
PhD
Milton Keynes, UK

Publications

11Publications

263Reads

822Profile Views

124PubMed Central Citations

Melanoma Stem Cell Sphere Formation Assay

Vol 7, Iss 8, 4/20/2017 DOI: https://doi.org/10.21769/BioProtoc.2233

bioprotocol

elf-renewal is the ability of cells to replicate themselves at every cell cycle. Throughout self-renewal in normal tissue homeostasis, stem cell number is maintained constant throughout life. Cancer stem cells (CSCs) share this ability with normal tissue stem cells and the sphere formation assay (SFA) is the gold standard assay to assess stem cells (or cancer stem cells) self-renewal potential in vitro. When single cells are plated at low density in stem cell culture medium, only the cells endowed with self-renewal are able to grow in tridimensional clusters usually named spheres. In the recent years, SFA has been used also to test the effect of several drugs, chemical and natural compounds or microenviromental components on stem cells self-renewal capacity. Here we will illustrate a detailed protocol to assess self-renewal of human melanoma stem cells, growing as melanospheres.

View Article
April 2017
18 Reads

Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells.

Stem Cells 2016 10 28;34(10):2449-2460. Epub 2016 Jun 28.

Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2413DOI Listing
October 2016
45 Reads
2 Citations
6.523 Impact Factor

PIM kinases as therapeutic targets against advanced melanoma.

Oncotarget 2016 Aug;7(34):54897-54912

Program of Cellular and Molecular Oncogenesis, Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.10703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342389PMC
August 2016
27 Reads
5 Citations
6.360 Impact Factor

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.

Pigment Cell Melanoma Res 2016 May 21;29(3):317-28. Epub 2016 Mar 21.

Program of Cellular and Molecular Oncogenesis, Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840066PMC
May 2016
51 Reads
3 Citations
4.620 Impact Factor

Heterogeneity in Melanoma.

Cancer Treat Res 2016 ;167:1-15

Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22539-5_1DOI Listing
January 2016
21 Reads
6 Citations

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010

Cancer Immunol Immunother. 2011 Jun;60(6):901-7.

Cancer Immunology Immunotherapy

NIBIT (acronym for the Network Italiano per la Bioterapia dei Tumori—Italian Network for Tumor Biotherapy) is a non-profit association created in 2004 to promote and foster scientific and operative interactions among Italian professionals involved in the field of cancer bioimmunotherapy. To date, more than 100 members representing over 40 national academic, regulatory, and industrial groups are part of the NIBIT. Aim of the annual meeting of the NIBIT is the discussion of recent preclinical and clinical results obtained by various Italian groups of the Network in the field of cancer immunology and biotherapy. Traditionally, the NIBIT meeting also hosts foreign speakers for keynote lectures on hot topics in the NIBIT field of interest.

View Article
June 2011
14 Reads

Spheres of influence in cancer stem cell biology.

J Invest Dermatol 2011 Feb 21;131(2):546-7. Epub 2010 Oct 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2010.305DOI Listing
February 2011
11 Reads
1 Citation
7.220 Impact Factor

Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.

J Invest Dermatol 2010 Jul 8;130(7):1877-86. Epub 2010 Apr 8.

Department of Experimental Oncology, Fondazione IRCSS, Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2010.69DOI Listing
July 2010
34 Reads
32 Citations
7.220 Impact Factor

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.

J Immunol 2010 Jun 26;184(11):6545-51. Epub 2010 Apr 26.

Unit of Immunotherapy of Human Tumors, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.0903879DOI Listing
June 2010
14 Reads
48 Citations
4.922 Impact Factor